Efficacy of Omaveloxolone in Friedreich's Ataxia: <scp>Delayed‐Start</scp> Analysis of the <scp>MOXIe</scp> Extension-Reference-Cited by-同舟云学术

Efficacy of Omaveloxolone in Friedreich's Ataxia: Delayed‐Start Analysis of the MOXIe Extension

Published:2022-11-29 Issue:2 Volume:38 Page:313-320
ISSN:0885-3185
Container-title:Movement Disorders
language:en
Short-container-title:Movement Disorders

Author:

Lynch David R.¹^ORCID,Chin Melanie P.²,Boesch Sylvia³,Delatycki Martin B.⁴,Giunti Paola⁵,Goldsberry Angie²,Hoyle J. Chad⁶,Mariotti Caterina⁷^ORCID,Mathews Katherine D.⁸,Nachbauer Wolfgang³,O'Grady Megan²,Perlman Susan⁹,Subramony S.H.¹⁰,Wilmot George¹¹,Zesiewicz Theresa¹²,Meyer Colin J.²

Affiliation:

1. Division of Neurology Children's Hospital of Philadelphia Philadelphia Pennsylvania USA

2. Reata Pharmaceuticals Dallas Texas USA

3. Department of Neurology Medical University Innsbruck Innsbruck Austria

4. Victorian Clinical Genetics Services Murdoch Children's Research Institute Parkville Victoria Australia

5. University College London Hospital London United Kingdom

6. Department of Neurology Ohio State University College of Medicine Columbus Ohio USA

7. IRCCS–Istituto Neurologico Carlo Besta Milan Italy

8. Department of Pediatrics University of Iowa Carver College of Medicine Iowa City Iowa USA

9. Department of Neurology University of California Los Angeles Los Angeles California USA

10. Department of Neurology, McKnight Brain Institute University of Florida Health System Gainesville Florida USA

11. Department of Neurology Emory University School of Medicine Atlanta Georgia USA

12. Department of Neurology University of South Florida Ataxia Research Center Tampa Florida USA

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mds.29286

Reference14 articles.

1. Safety and Efficacy of Omaveloxolone in Friedreich Ataxia ( MOXIe Study)

2. Predictors of loss of ambulation in Friedreich's ataxia

3. Friedreich Ataxia

4. Mortality in Friedreich Ataxia

5. FRIEDREICH'S ATAXIA: A CLINICAL AND GENETIC STUDY OF 90 FAMILIES WITH AN ANALYSIS OF EARLY DIAGNOSTIC CRITERIA AND INTRAFAMILIAL CLUSTERING OF CLINICAL FEATURES

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging antioxidant therapies in Friedreich’s ataxia;Frontiers in Pharmacology;2024-02-06

2. Structural modification of C2-substituents on 1,4-bis(arylsulfonamido)benzene or naphthalene-N,N′-diacetic acid derivatives as potent inhibitors of the Keap1-Nrf2 protein-protein interaction;European Journal of Medicinal Chemistry;2024-02

3. Omaveloxolone for the treatment of Friedreich ataxia: clinical trial results and practical considerations;Expert Review of Neurotherapeutics;2024-01-25

4. Important advances in movement disorders research in 2023;The Lancet Neurology;2024-01

5. Omaveloxolone: a groundbreaking milestone as the first FDA-approved drug for Friedreich ataxia;Trends in Molecular Medicine;2024-01